Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.

@article{Przepiorka1996TacrolimusAM,
  title={Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.},
  author={Donna Przepiorka and Cindy M Ippoliti and Issa F. Khouri and M Woo and R C Mehra and D Le Bherz and Sergio A. Giralt and James L. Gajewski and Harald Fischer and Herbert Fritsche and A B Deisseroth and Karen L Cleary and Richard E. Champlin and K van Besien and B S Andersson and R Maher and William E. Fitzsimmons},
  journal={Blood},
  year={1996},
  volume={88 11},
  pages={4383-9}
}
Thirty adults with leukemia or lymphoma undergoing marrow transplantation from HLA-compatible unrelated donors received tacrolimus (FK506), a new immunosuppressive macrolide lactone, and minidose methotrexate to prevent acute graft-versus-host disease (GVHD). The group had a median age of 36 years (range 21 to 49 years). Twenty-four patients had advanced disease, and 11 were resistant to conventional therapy. Tacrolimus was administered at 0.03 mg/kg/d intravenously (i.v.) by continuous… CONTINUE READING